Optomed Q4 (Initial take): Sales in line; EBIT impacted by a one-off cost - Redeye

Redeye provides an initial take following the release of Optomed’s Q4 2025 report. Sales were in line with our projections, while EBIT came in below expectations, mainly due to a one-off cost. Overall, we view the report as decent, but expect some pressure on the share today given the weaker-than-expected EBIT and limited awareness of the tough comparables. We will publish a research update shortly; while we do not anticipate any material changes to our fair value range, we may implement some downward revisions to our short-term sales estimates.

Länk till analysen i sin helhet: https://www.redeye.se/research/1148435/optomed-q4-initial-take-sales-in-line-ebit-impacted-by-a-one-off-cost?utm_source=finwire&utm_medium=RSS